WO1995012612A1 - Inhibiteurs di- et tripeptidiques substitues de l'enzyme proteine:la farnesyle transferase - Google Patents
Inhibiteurs di- et tripeptidiques substitues de l'enzyme proteine:la farnesyle transferase Download PDFInfo
- Publication number
- WO1995012612A1 WO1995012612A1 PCT/US1994/011553 US9411553W WO9512612A1 WO 1995012612 A1 WO1995012612 A1 WO 1995012612A1 US 9411553 W US9411553 W US 9411553W WO 9512612 A1 WO9512612 A1 WO 9512612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- obn
- tyr
- cbz
- ser
- conh
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the compounds of Formula I may be prepared by solid phase peptide synthesis on a peptide synthesizer, for example, an Applied Biosystems 431A peptide synthesizer using activated esters or anhydrides of Boc or Fmoc protected amino acids, acid chlorides, isocyanates, isothiocyanates, etc., on PAM, MBHA, or NH 2 -Rink resins with solution phase modifications to the carboxyl terminus as appropriate.
- Methodology for the solid phase synthesis of peptides is widely known to those skilled in the art thereof (see, for example: J.M. Stewart and J.D. Young in Solid Phase Peptide Synthesis: Pierce Chemical Co.; Rockford, IL (1984); Fields G.B. and Noble R.L.
- the compounds of Formula I may be prepared by simultaneous multiple solid phase syntheses using an apparatus described by S. H. DeWitt, et al. , Proc. Natl. Acad. Sci. USA. 9 . 0:6909 (1993), and referred to by the trademark, DiversomerTM, both trademark and apparatus being owned in whole by the Warner-Lambert Company.
- the multiple solid phase synthesis apparatus is currently the subject of now abandoned US Serial 07/958,383 filed October 8, 1992 and pending continuation-in-part US Serial 08/012,557 filed February 2, 1993.
- the pharmaceutical preparation is preferably in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- Step 3 BnNHCO-His (Tr) -Tyr(OBn) -Ser(OBn) -CQ 2 Me
- Example 20 by substituting Boc- ( ⁇ !-Me)Tyr(OBn) for Boc-Tyr(OBn) , the title compound was obtained, mp 66-78°C; ES-MS 690 (m+1) .
- EXAMPLE 23 N- (2-Phenylethyl) -N a - fN- f (phenylmethoxy) carbonyl! - L-histidyl! -0- (phenylmethyl) -L-tyrosinamide ⁇ Cbz-His-Tyr(OBn) -C0NHCH CH 2 Ph) According to Example 19, Step 3, by substituting
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ275691A NZ275691A (en) | 1993-11-05 | 1994-10-12 | Di and tripeptides and compositions thereof which inhibit farnesyl transferase |
AU79760/94A AU681454B2 (en) | 1993-11-05 | 1994-10-12 | Substituted DI- and tripeptide inhibitors of protein:farnesyl transferase |
JP51322495A JP3597863B2 (ja) | 1993-11-05 | 1994-10-12 | タンパク質:ファルネシルトランスフェラーゼの置換されたジ‐およびトリペプチド阻害剤 |
EP94930725A EP0730605A1 (fr) | 1993-11-05 | 1994-10-12 | Inhibiteurs di- et tripeptidiques substitues de l'enzyme proteine:la farnesyle transferase |
FI961819A FI961819A (fi) | 1993-11-05 | 1996-04-29 | Proteiini:farnesyylitransferaasin substituoidut di- ja tripeptidi-inhibiittorit |
NO961814A NO961814L (no) | 1993-11-05 | 1996-05-03 | Substituerte di- og tripetidinhibitorer for protein:farnesyl-transferase |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14873593A | 1993-11-05 | 1993-11-05 | |
US30330194A | 1994-09-13 | 1994-09-13 | |
US08/303,301 | 1994-09-13 | ||
US08/148,735 | 1994-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995012612A1 true WO1995012612A1 (fr) | 1995-05-11 |
Family
ID=26846110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/011553 WO1995012612A1 (fr) | 1993-11-05 | 1994-10-12 | Inhibiteurs di- et tripeptidiques substitues de l'enzyme proteine:la farnesyle transferase |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0730605A1 (fr) |
JP (1) | JP3597863B2 (fr) |
KR (1) | KR100362338B1 (fr) |
AU (1) | AU681454B2 (fr) |
CA (1) | CA2170766A1 (fr) |
FI (1) | FI961819A (fr) |
HU (1) | HUT75308A (fr) |
NO (1) | NO961814L (fr) |
NZ (1) | NZ275691A (fr) |
WO (1) | WO1995012612A1 (fr) |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0675112A1 (fr) * | 1994-03-31 | 1995-10-04 | Bristol-Myers Squibb Company | Inhibiteurs de farnésyl-protéine-transférase contenant l'imidazole |
WO1996010034A2 (fr) * | 1994-09-29 | 1996-04-04 | Merck & Co., Inc. | Inhibiteurs de la transferase de proteines farnesylees exempts de thiol |
FR2736641A1 (fr) * | 1995-07-10 | 1997-01-17 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
EP0783318A1 (fr) * | 1994-09-29 | 1997-07-16 | Merck & Co. Inc. | Inhibiteurs de farnesyle-proteine transferase |
US5652257A (en) * | 1994-09-29 | 1997-07-29 | Merck & Co., Inc. | Heterocycle-containing inhibitors of farnesyl-protein transferase |
EP0787123A1 (fr) * | 1994-09-29 | 1997-08-06 | Merck & Co. Inc. | Inhibiteurs de farnesyle-proteine transferase |
WO1997044350A1 (fr) * | 1996-05-22 | 1997-11-27 | Warner-Lambert Company | Inhibiteurs de farnesyltransferase de proteines |
US5756528A (en) * | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998027109A1 (fr) * | 1996-12-17 | 1998-06-25 | Warner-Lambert Company | Inhibiteurs cycloalkyle de proteine farnesyltransferase |
FR2757855A1 (fr) * | 1996-12-30 | 1998-07-03 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
EP0892797A1 (fr) * | 1996-02-26 | 1999-01-27 | Bristol-Myers Squibb Company | Inhibiteurs de la farnesyl-transferase |
US5968965A (en) * | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5972984A (en) * | 1995-06-06 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1999055725A1 (fr) * | 1998-04-27 | 1999-11-04 | Warner-Lambert Company | Derives fonctionnalises de glycinamides, a chaine laterale alkyle et alcenyle, utilises comme inhibiteurs de la farnesyl-transferase |
US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6013662A (en) * | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
WO2000034313A1 (fr) * | 1998-12-10 | 2000-06-15 | F. Hoffmann-La Roche Ag | Inhibiteurs de la c-proteinase de procollagene |
US6124465A (en) * | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
US6166052A (en) * | 1998-03-11 | 2000-12-26 | Warner-Lambert Company | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers |
US6251919B1 (en) | 1998-02-27 | 2001-06-26 | Warner-Lambert | Heterocyclic substituted aniline calcium channel blockers |
US6291679B1 (en) | 1999-07-22 | 2001-09-18 | Rhone-Poulenc Rorer S.A. | Process for preparing benzoperhydroisoindole compounds |
US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
US6423689B1 (en) | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
US6441006B2 (en) | 1998-04-02 | 2002-08-27 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6627648B1 (en) | 1999-05-24 | 2003-09-30 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
WO2007093827A1 (fr) | 2006-02-15 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac) |
WO2008106692A1 (fr) | 2007-03-01 | 2008-09-04 | Novartis Vaccines And Diagnostics, Inc. | Inhibiteurs de pim kinase et procédés de leur utilisation |
WO2008144062A1 (fr) | 2007-05-21 | 2008-11-27 | Novartis Ag | Inhibiteurs du csf-1r, compositions et procédés d'utilisation |
WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
US7553854B2 (en) | 2006-04-19 | 2009-06-30 | Novartis Vaccines And Diagnostics, Inc. | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
WO2011046771A1 (fr) | 2009-10-14 | 2011-04-21 | Schering Corporation | Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés |
EP2336120A1 (fr) | 2007-01-10 | 2011-06-22 | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. | Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP) |
WO2011115725A2 (fr) | 2010-03-16 | 2011-09-22 | Dana-Farber Cancer Institute, Inc. | Composés d'indazole et leurs utilisations |
WO2011163330A1 (fr) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
WO2012024170A2 (fr) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
WO2012027236A1 (fr) | 2010-08-23 | 2012-03-01 | Schering Corporation | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
WO2012036997A1 (fr) | 2010-09-16 | 2012-03-22 | Schering Corporation | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
WO2012058210A1 (fr) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA) |
WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
WO2012145471A1 (fr) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline |
WO2013063214A1 (fr) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
EP2698157A1 (fr) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
US20140094614A1 (en) * | 2011-10-26 | 2014-04-03 | Allergan, Inc. | Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators |
WO2014052563A2 (fr) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Nouveaux composés inhibiteurs de erk |
WO2014085216A1 (fr) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Compositions et procédés pour traiter le cancer |
WO2014100065A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituées en tant qu'inhibiteurs de hdm2 |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
WO2016020864A1 (fr) | 2014-08-06 | 2016-02-11 | Novartis Ag | Inhibiteurs de protéine kinase c et leurs procédés d'utilisation |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2018058022A1 (fr) | 2016-09-26 | 2018-03-29 | Merck Sharp & Dohme Corp. | Anticorps anti-cd27 |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2018190719A2 (fr) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anticorps anti-sirp alpha |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10144730B2 (en) | 2011-11-17 | 2018-12-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2019152642A1 (fr) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anticorps bispécifiques anti-pd-1/lag3 |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10906889B2 (en) | 2013-10-18 | 2021-02-02 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
US11040957B2 (en) | 2013-10-18 | 2021-06-22 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
US11096950B2 (en) | 2006-11-01 | 2021-08-24 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
US11142507B2 (en) | 2015-09-09 | 2021-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US11826365B2 (en) | 2009-12-29 | 2023-11-28 | Dana-Farber Cancer Institute, Inc. | Type II raf kinase inhibitors |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005044780A1 (ja) * | 2003-11-10 | 2007-05-17 | 杏林製薬株式会社 | アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤 |
TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0523873A1 (fr) * | 1991-06-28 | 1993-01-20 | Merck & Co. Inc. | Inhibiteurs non-substrat peptidiques de la farnesyl-protéine-transferase |
-
1994
- 1994-10-12 WO PCT/US1994/011553 patent/WO1995012612A1/fr not_active Application Discontinuation
- 1994-10-12 JP JP51322495A patent/JP3597863B2/ja not_active Expired - Fee Related
- 1994-10-12 EP EP94930725A patent/EP0730605A1/fr not_active Withdrawn
- 1994-10-12 AU AU79760/94A patent/AU681454B2/en not_active Ceased
- 1994-10-12 CA CA002170766A patent/CA2170766A1/fr not_active Abandoned
- 1994-10-12 HU HU9601193A patent/HUT75308A/hu unknown
- 1994-10-12 KR KR1019960702309A patent/KR100362338B1/ko not_active IP Right Cessation
- 1994-10-12 NZ NZ275691A patent/NZ275691A/en unknown
-
1996
- 1996-04-29 FI FI961819A patent/FI961819A/fi unknown
- 1996-05-03 NO NO961814A patent/NO961814L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0523873A1 (fr) * | 1991-06-28 | 1993-01-20 | Merck & Co. Inc. | Inhibiteurs non-substrat peptidiques de la farnesyl-protéine-transferase |
Non-Patent Citations (2)
Title |
---|
K.MEDZIHRADSZKY ET AL: "Effect of secondary enzyme-substrate interactions on the cleavage of synthetic peptides by pepsin", BIOCHEMISTRY., vol. 9, no. 5, 3 March 1970 (1970-03-03), EASTON, PA US, pages 1154 - 1162 * |
T.R.HOLLANDS ET AL: "Action of pepsin on cationic synthetic substrates", BIOCHEMISTRY., vol. 8, no. 2, February 1969 (1969-02-01), EASTON, PA US, pages 575 - 585 * |
Cited By (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0675112A1 (fr) * | 1994-03-31 | 1995-10-04 | Bristol-Myers Squibb Company | Inhibiteurs de farnésyl-protéine-transférase contenant l'imidazole |
EP0787123A4 (fr) * | 1994-09-29 | 1999-10-13 | Merck & Co Inc | Inhibiteurs de farnesyle-proteine transferase |
WO1996010034A2 (fr) * | 1994-09-29 | 1996-04-04 | Merck & Co., Inc. | Inhibiteurs de la transferase de proteines farnesylees exempts de thiol |
EP0783318A4 (fr) * | 1994-09-29 | 1999-10-20 | Merck & Co Inc | Inhibiteurs de farnesyle-proteine transferase |
WO1996010034A3 (fr) * | 1994-09-29 | 1996-05-09 | Merck & Co Inc | Inhibiteurs de la transferase de proteines farnesylees exempts de thiol |
EP0783318A1 (fr) * | 1994-09-29 | 1997-07-16 | Merck & Co. Inc. | Inhibiteurs de farnesyle-proteine transferase |
US5652257A (en) * | 1994-09-29 | 1997-07-29 | Merck & Co., Inc. | Heterocycle-containing inhibitors of farnesyl-protein transferase |
EP0787123A1 (fr) * | 1994-09-29 | 1997-08-06 | Merck & Co. Inc. | Inhibiteurs de farnesyle-proteine transferase |
US5756528A (en) * | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5972984A (en) * | 1995-06-06 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CN1096448C (zh) * | 1995-07-10 | 2002-12-18 | 罗纳-布朗克·罗莱尔股份有限公司 | 新的法呢基转移酶的抑制剂,其制备方法及其药物组合物 |
FR2736641A1 (fr) * | 1995-07-10 | 1997-01-17 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
WO1997003050A1 (fr) * | 1995-07-10 | 1997-01-30 | Rhone-Poulenc Rorer S.A. | DERIVES DE 4,9-ETHANO-BANZO(f)ISOINDOLE COMME INHIBITEURS DE FARNESYL TRANSFERASE |
EA000797B1 (ru) * | 1995-07-10 | 2000-04-24 | Рон-Пуленк Роре С.А. | Новые ингибиторы фарнезилтрансферазы, способы их получения и содержащая их фармацевтическая композиция |
US5936097A (en) * | 1995-07-10 | 1999-08-10 | Rhone-Poulenc Rorer, S.A. | 4,9-ethano-benzo(F)isoindole derivatives as farnesyl transferase inhibitors |
US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5968965A (en) * | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP1481975A1 (fr) * | 1996-02-26 | 2004-12-01 | Bristol-Myers Squibb Company | Inhibiteurs de la farnésyl protéine transférase |
EP0892797A1 (fr) * | 1996-02-26 | 1999-01-27 | Bristol-Myers Squibb Company | Inhibiteurs de la farnesyl-transferase |
EP0892797A4 (fr) * | 1996-02-26 | 2004-10-20 | Bristol Myers Squibb Co | Inhibiteurs de la farnesyl-transferase |
WO1997044350A1 (fr) * | 1996-05-22 | 1997-11-27 | Warner-Lambert Company | Inhibiteurs de farnesyltransferase de proteines |
US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
US6281194B1 (en) | 1996-12-17 | 2001-08-28 | Warner-Lambert Company | Cycloalkyl inhibitors of protein farnesyltransferase |
WO1998027109A1 (fr) * | 1996-12-17 | 1998-06-25 | Warner-Lambert Company | Inhibiteurs cycloalkyle de proteine farnesyltransferase |
WO1998029390A1 (fr) * | 1996-12-30 | 1998-07-09 | Rhone-Poulenc Rorer S.A. | Inhibiteurs de farnesyle transferase |
US6013662A (en) * | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
US6218406B1 (en) | 1996-12-30 | 2001-04-17 | Aventis Pharma S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
FR2757855A1 (fr) * | 1996-12-30 | 1998-07-03 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
US6124465A (en) * | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
US6423689B1 (en) | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
US6251919B1 (en) | 1998-02-27 | 2001-06-26 | Warner-Lambert | Heterocyclic substituted aniline calcium channel blockers |
US6166052A (en) * | 1998-03-11 | 2000-12-26 | Warner-Lambert Company | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers |
US6989448B2 (en) | 1998-03-11 | 2006-01-24 | Lain-Yen Hu | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers |
US6469038B1 (en) | 1998-03-11 | 2002-10-22 | Warner-Lambert Company | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers |
US6441007B1 (en) | 1998-04-02 | 2002-08-27 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6441006B2 (en) | 1998-04-02 | 2002-08-27 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
WO1999055725A1 (fr) * | 1998-04-27 | 1999-11-04 | Warner-Lambert Company | Derives fonctionnalises de glycinamides, a chaine laterale alkyle et alcenyle, utilises comme inhibiteurs de la farnesyl-transferase |
US6369034B1 (en) | 1998-04-27 | 2002-04-09 | Warner-Lambert Company | Functionalized alkyl and alenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors |
US6951918B2 (en) | 1998-12-10 | 2005-10-04 | Syntex (U.S.A.) Llc | Peptidic procollagen C-proteinase inhibitors |
US6426402B1 (en) | 1998-12-10 | 2002-07-30 | Syntex (U.S.A.) Llc | Peptidic procollagen C-proteinase inhibitors |
WO2000034313A1 (fr) * | 1998-12-10 | 2000-06-15 | F. Hoffmann-La Roche Ag | Inhibiteurs de la c-proteinase de procollagene |
US6627648B1 (en) | 1999-05-24 | 2003-09-30 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6291679B1 (en) | 1999-07-22 | 2001-09-18 | Rhone-Poulenc Rorer S.A. | Process for preparing benzoperhydroisoindole compounds |
WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
WO2007093827A1 (fr) | 2006-02-15 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac) |
US8710048B2 (en) | 2006-04-19 | 2014-04-29 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
US7553854B2 (en) | 2006-04-19 | 2009-06-30 | Novartis Vaccines And Diagnostics, Inc. | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
US8173689B2 (en) | 2006-04-19 | 2012-05-08 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
EP2946778A1 (fr) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras |
EP2698157A1 (fr) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
US11096950B2 (en) | 2006-11-01 | 2021-08-24 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2336120A1 (fr) | 2007-01-10 | 2011-06-22 | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. | Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP) |
EP2805945A1 (fr) | 2007-01-10 | 2014-11-26 | MSD Italia S.r.l. | Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase |
WO2008106692A1 (fr) | 2007-03-01 | 2008-09-04 | Novartis Vaccines And Diagnostics, Inc. | Inhibiteurs de pim kinase et procédés de leur utilisation |
WO2008144062A1 (fr) | 2007-05-21 | 2008-11-27 | Novartis Ag | Inhibiteurs du csf-1r, compositions et procédés d'utilisation |
WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
EP3103791A1 (fr) | 2007-06-27 | 2016-12-14 | Merck Sharp & Dohme Corp. | Dérivés de4-carboxybenzylamino utilisés comme inhibiteurs de l'histone désacétylase |
WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
US9505784B2 (en) | 2009-06-12 | 2016-11-29 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
WO2011046771A1 (fr) | 2009-10-14 | 2011-04-21 | Schering Corporation | Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés |
US11826365B2 (en) | 2009-12-29 | 2023-11-28 | Dana-Farber Cancer Institute, Inc. | Type II raf kinase inhibitors |
US8987275B2 (en) | 2010-03-16 | 2015-03-24 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
WO2011115725A2 (fr) | 2010-03-16 | 2011-09-22 | Dana-Farber Cancer Institute, Inc. | Composés d'indazole et leurs utilisations |
WO2011163330A1 (fr) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
EP3330377A1 (fr) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
EP4079856A1 (fr) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
WO2012024170A2 (fr) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
WO2012027236A1 (fr) | 2010-08-23 | 2012-03-01 | Schering Corporation | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
WO2012036997A1 (fr) | 2010-09-16 | 2012-03-22 | Schering Corporation | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
EP3327125A1 (fr) | 2010-10-29 | 2018-05-30 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
WO2012058210A1 (fr) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA) |
EP3766975A1 (fr) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
WO2012145471A1 (fr) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline |
US10172832B2 (en) | 2011-10-26 | 2019-01-08 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
US9351948B2 (en) | 2011-10-26 | 2016-05-31 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
US20140094614A1 (en) * | 2011-10-26 | 2014-04-03 | Allergan, Inc. | Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators |
US9579307B2 (en) | 2011-10-26 | 2017-02-28 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
US10993931B2 (en) | 2011-10-26 | 2021-05-04 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
US9974772B2 (en) | 2011-10-26 | 2018-05-22 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
US8993780B2 (en) * | 2011-10-26 | 2015-03-31 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
WO2013063214A1 (fr) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
US10144730B2 (en) | 2011-11-17 | 2018-12-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
US10981903B2 (en) | 2011-11-17 | 2021-04-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
EP3919620A1 (fr) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Compositions d'acide nucléique interférent court (sina) |
WO2014052563A2 (fr) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Nouveaux composés inhibiteurs de erk |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10787436B2 (en) | 2012-10-18 | 2020-09-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014085216A1 (fr) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Compositions et procédés pour traiter le cancer |
WO2014100065A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituées en tant qu'inhibiteurs de hdm2 |
WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
US11040957B2 (en) | 2013-10-18 | 2021-06-22 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
US10906889B2 (en) | 2013-10-18 | 2021-02-02 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2016020864A1 (fr) | 2014-08-06 | 2016-02-11 | Novartis Ag | Inhibiteurs de protéine kinase c et leurs procédés d'utilisation |
EP3514151A1 (fr) | 2014-08-06 | 2019-07-24 | Novartis AG | Inhibiteurs de protéine kinase c et leurs procédés d'utilisation |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US11325910B2 (en) | 2015-03-27 | 2022-05-10 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US11142507B2 (en) | 2015-09-09 | 2021-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2018058022A1 (fr) | 2016-09-26 | 2018-03-29 | Merck Sharp & Dohme Corp. | Anticorps anti-cd27 |
WO2018190719A2 (fr) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anticorps anti-sirp alpha |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2019152642A1 (fr) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anticorps bispécifiques anti-pd-1/lag3 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
Also Published As
Publication number | Publication date |
---|---|
KR100362338B1 (ko) | 2003-04-08 |
FI961819A0 (fi) | 1996-04-29 |
NZ275691A (en) | 1998-03-25 |
NO961814L (no) | 1996-05-06 |
FI961819A (fi) | 1996-04-29 |
AU681454B2 (en) | 1997-08-28 |
JP3597863B2 (ja) | 2004-12-08 |
NO961814D0 (no) | 1996-05-03 |
HUT75308A (en) | 1997-05-28 |
CA2170766A1 (fr) | 1995-05-11 |
HU9601193D0 (en) | 1996-07-29 |
AU7976094A (en) | 1995-05-23 |
JPH09504547A (ja) | 1997-05-06 |
EP0730605A1 (fr) | 1996-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU681454B2 (en) | Substituted DI- and tripeptide inhibitors of protein:farnesyl transferase | |
AU682906B2 (en) | Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase | |
AU699629B2 (en) | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase | |
AU3971295A (en) | Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase | |
CA2008116C (fr) | Derives de glycine | |
US5470833A (en) | Endothelin antagonistic peptide derivatives | |
EP1006122B1 (fr) | Derives de phenylethylamine | |
US5830868A (en) | Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase | |
US5763577A (en) | Substituted tetra- and pentapeptide inhibitors of protein: farnesyl transferase | |
AU721786C (en) | Cycloalkyl inhibitors of protein farnesyltransferase | |
MXPA97003208A (en) | Tetra-y pentapeptidos substituidos deproteina inhibitors, farnesil transfer | |
KR840000054B1 (ko) | 티모신 α₁의 제조방법 | |
CZ9902807A3 (cs) | Způsob výroby organických látek, zejména karba analogů peptidů | |
HRP930498A2 (en) | Glycine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BG BY CA CZ EE FI GE HU JP KG KR KZ LT LV MD NO NZ PL RO RU SI SK TJ UA UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2170766 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 275691 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994930725 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 961819 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1994930725 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994930725 Country of ref document: EP |